Get the latest news, insights, and market updates on TLSI (TriSalus Life Sciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Rockwell Medical (RMTI) Reports Q3 Loss, Lags Revenue Estimates
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -25.00% and -5.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 12, 2025 - $TLSI
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
WESTMINSTER, Colo., November 11, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November: Nov 11, 2025 - $TLSI
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
WESTMINSTER, Colo., November 10, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (Universi Nov 10, 2025 - $TLSI
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of +31.82% and +3.66%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 7, 2025 - $TLSI
biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates
biote Corp. (BTMD) delivered earnings and revenue surprises of +340.00% and +0.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 5, 2025 - $TLSI
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
WESTMINSTER, Colo., October 30, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be iss Oct 30, 2025 - $TLSI
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
WESTMINSTER, Colo., August 28, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the follo Aug 28, 2025 - $TLSI
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER, August 12, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. Aug 12, 2025 - $TLSI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple